Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae

Chemotherapy

Volumn 49, Issue 1-2, 2003, Pages 33-35

  Lemmen, S W ^a   Hafner H ^a   Klik, S ^a   Lutticken R ^a   Zolldann, D ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Bactericidal activity; Levofloxacin; Moxifloxacin

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COLONY-FORMING UNITS ASSAY; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES; SERUM BACTERICIDAL TEST; SPECIES SPECIFICITY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0344080440     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069779     Document Type: Article

References (13)

1. Lemmen SW, Hauer T, Engels I, Daschner FD: Serumbakterizide Aktivität von Cefotiam-Hexetil gegen Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus und Escherischia coli. Antiinfect Drugs Chemother 1995;13:197-199.
2. National Committee for Clinical Laboratory Standards: Methodology for the serum bactericidal test: Proposed guidelines. Document/M21-T. NCCLS, Villanova, 1992.
3. Stass H, Kubitza D: Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43(suppl B):83-90.
4. Simon C, Stille W: Antibiotika-Therapie in Klinik und Praxis. Stuttgart, Schattauer, 2000, pp 127-130.
5. Boeckh M, Lode H: Die Bedeutung der Serum-bakterizidie für den Erfolg einer antibakteriellen Therapie; in Paul-Ehrlich-Gesellschaft, Wiedemann B (Hrsg). Parameter für die Beurteilung der Erregerempfindlichkeit. FAC 9-2. Fortschr Antimikrob Antineoplast Chemother. Munchen, Futuramed Verlag, 1990, pp 203-221.
6. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB: Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987;83:218-222.
7. Hoogkamp-Korstanje JAA, Roelofs-Willemse J: Comparative in vitro activity of moxifloxacin against gram-positive clinical isolates. J Antimicrob Chemother 2000;45:31-39.
8. Bauernfeind A: Comparison of the antimicrobial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clina-floxacin, levofloxacin and ciprofloxacin. J An-timicrob Chemother 1997;40:639-651.
9. Morissey I, Smith JT: Activity of 4-quinolones against Pseudomonas aeruginosa. Arzneimittelforschung 1994;44:1157-1161.
10. Forschungswerkstatt Moxifloxacin. Chemo-therapiejournal 2001;10(suppl 17):1-6.
11. Krasemann C, Meyer JM, Springsklee M: Moxifloxacin in community acquired pneumonia - A bacteriological and clinical meta-analysis (abstract 205). Clin Microbiol Infect 1999; 5(suppl 3):139.
12. Krasemann C, Meyer JM, Springsklee M: Moxifloxacin in acute sinusitis - A bacteriological meta-analysis (abstract 204). Clin Microbiol Infect 1999;5(suppl 3):139.
13. Siefert HM, Kohlsdorfer C, Steinke W, Witt A: Pharmacokinetics of 8-methoxyquinolone, moxifloxacin: Tissue distribution in male rats. J Antimicrob Chemother 1999;43 B:61-67.